Cheek Filler Before and After: 1 ml vs 2 ml Results

No label or trial we found describes what 1 mL looks like in a given cheek — the sources give scale, not a picture.

The Restylane Contour label caps a single session at 6 mL in the cheeks and midface, a ceiling rather than a target, and in its cheek trial the median volume for initial treatment plus touch-up was 3.80 mL for both cheeks together.

A 1 mL treatment sits well below that measured median.

The trial's other measured volume is 1.95 mL — the median re-treatment volume at week 48, a top-up for people the study had treated before rather than a restart.

Between them, the numbers explain why a before-and-after cannot be read as a milliliter chart: what 1 mL shows depends on the face it goes into — sources treat results as varying from person to person — and judging it is an in-person job for a licensed provider.

Gallery captions need two cautions.

One: "a syringe" is not automatically 1 mL — syringe sizes vary by product, and Revanesse's, for example, at 1.0 or 1.2 mL — and a "half syringe" is a clinic pricing practice, not a labeled size.

Two: the trial figures on this page are not split by cheek zone, so nothing here verifies a "lateral cheek" label on a photo.

How practices quote syringes, milliliters and price is its own subject — our cheek filler guide covers it.

Two milliliters has a near-exact anchor in the trial data: 1.95 mL, the median re-treatment volume at week 48 in the Restylane Contour cheek trial — a top-up for people the study had treated before, not a first treatment.

A first treatment of 2 mL sits a little over half of that trial's 3.80 mL median for initial treatment plus touch-up.

How results held over 48 weeks comes from a different group in the Contour cheek trial — subjects randomized head-to-head against Juvéderm Voluma XC and treated with a needle, not the group the milliliter medians above describe: blinded evaluators rated 91.2% of Restylane Contour subjects and 87.7% of Voluma XC subjects responders at week 12, 88.5% and 83.1% at week 24, 72.1% and 83.6% at week 36, and 62.8% and 65.1% at week 48.

The rates decline rather than switch off, and the lead changed hands as the study went on; the study — sponsored by Contour's maker Galderma as a non-inferiority trial — ranks neither product.

Those responder rates were not measured for a 2 mL treatment, so they are not the result to project onto 2 mL.

The first weeks of any "after" have a measured downside: Allergan reports that in the Voluma XC cheek study the most common side effects — tenderness, swelling, firmness, lumps/bumps, bruising, pain, redness, discoloration and itching — were moderate and generally lasted 2 to 4 weeks.

The "before" the labels describe is age-related: Juvéderm Voluma XC is approved for deep injection for cheek augmentation to correct age-related midface volume deficit in adults over 21 — approved on 2013-10-22, the earliest approval among the six US fillers carrying an FDA-approved cheek/midface indication as of 2026-10-20.

What the labels did not do is study every older age.

Juvéderm's Important Safety Information states that Voluma XC safety was not studied in patients under 35 or over 65 for cheek augmentation, and that Voluma was not studied in people with significant loose skin of the chin, neck or jaw. "Not studied" is not "proven unsafe" — it means the label carries no safety data for those groups, which makes it a consultation question rather than a ban.

One cheek-area trial in our research did publish an older median age: the pivotal study of VYC-12L — Allergan's 12 mg/mL hyaluronic acid gel with 0.3% lidocaine, the study gel our research matches to SkinVive, an intradermal treatment approved to improve cheek skin smoothness rather than add volume — enrolled 131 treated subjects against 71 controls with a median age of 58, and 57.9% of treated participants improved at least one grade in cheek smoothness at month 1, with responder rates staying consistent through 6 months.

Read the approvals and the labels are sex-blind: Voluma XC's cheek indication reads "adults over the age of 21," with no male or female wording, and Juvéderm's not-studied age cutoffs name no sexes either.

The trial figures on this page — the responder rates and the milliliter medians — are reported for whole study groups, not split by sex; the one makeup figure on this page is the smoothness trial's 86.1% female.

No number here is a men's number or a women's number.

That gap cuts one way for galleries: a practice's male before-and-afters are marketing photos, not published trial data, and the skepticism in the section below applies to them the same.

What a 1 mL or 2 mL treatment shows on any one man depends on his midface — the consultation's job to assess, using the same questions any patient should ask.

Start with what the evidence cannot give you: we found no label, trial or professional-body source that defines an "overfilled" look or puts a rate on it, so any checklist of "signs you have had too much" has nothing in our sources behind it.

What the sources do support is narrower.

Lumps and bumps are on the watch list — Allergan lists them among the most common side effects in the Voluma XC cheek study, moderate and generally lasting 2 to 4 weeks — so a lump that outlasts that window is a question for your provider.

And if an HA result is not what you wanted, Cleveland Clinic says hyaluronidase dissolves hyaluronic acid filler wherever it sits — lips, cheeks, lower eyelids — and our filler dissolving guide covers the process, its limits and who may perform it.

Then read every gallery as an advertisement.

Under the FTC's Endorsement Guides, a before-and-after picture that appears with a results claim conveys that the result shown is what consumers can generally expect — and where they cannot, the agency's own example calls the ad deceptive.

No photo can promise your result: results vary from person to person.

The American Academy of Dermatology's list of questions to ask before a cosmetic procedure includes: